1. Gershon AA, Gershon MD.. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev. 2013;26:728–43. doi: 10.1128/CMR.00052-13. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
2. Mitchell BM, Bloom DC, Cohrs RJ, Gilden DH, Kennedy PG. Herpes simplex virus-1 and varicella-zoster virus latency in ganglia. J Neurovirol. 2003;9:194–204. doi: 10.1080/13550280390194000. [PubMed] [CrossRef] [Google Scholar]
3. Levin MJ, Cai GY, Manchak MD, Pizer LI. Varicella-zoster virus DNA in cells isolated from human trigeminal ganglia. J Virol. 2003;77:6979–87. [PMC free article] [PubMed] [Google Scholar]
4. Depledge DP, Ouwendijk WJD, Sadaoka T, Braspenning SE, Mori Y, Cohrs RJ, Verjans GMGM, Breuer J. A spliced latency-associated VZV transcript maps antisense to the viral transactivator gene 61. Nat Commun. 2018;9:1167. doi: 10.1038/s41467-018-03569-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
5. Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol. 2010;342:341–57. doi: 10.1007/82_2010_31. [PubMed] [CrossRef] [Google Scholar]
6. Mehta SK, Cohrs RJ, Forghani B, Zerbe G, Gilden DH, Pierson DL. Stress-induced subclinical reactivation of varicella zoster virus in astronauts. J Med Virol. 2004;72:174–79. doi: 10.1002/jmv.10555. [PubMed] [CrossRef] [Google Scholar]
7. Ljungman P, Lonnqvist B, Gahrton G, Ringden O, Sundqvist VA, Wahren B. Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis. 1986;153:840–47. [PubMed] [Google Scholar]
8. Cinque P, Bossolasco S, Vago L, Fornara C, Lipari S, Racca S, Lazzarin A, Linde A. Varicella-zoster virus (VZV) DNA in cerebrospinal fluid of patients infected with human immunodeficiency virus: VZV disease of the central nervous system or subclinical reactivation of VZV infection?Clin Infect Dis. 1997;25:634–39. [PubMed] [Google Scholar]
9. Schunemann S, Mainka C, Wolff MH. Subclinical reactivation of varicella-zoster virus in immunocompromised and immunocompetent individuals. Intervirology. 1998;41:98–102. doi: 10.1159/000024920. [PubMed] [CrossRef] [Google Scholar]
10. Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis. 1992;165:119–26. [PubMed] [Google Scholar]
11. Weinberg A, Lazar AA, Zerbe GO, Hayward AR, Chan ISF, Vessey R, Silber JL, MacGregor RR, Chan K, Gershon AA, et al. Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. J Infect Dis. 2010;201:1024–30. doi: 10.1086/651199. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
12. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833. doi: 10.1136/bmjopen-2014-004833. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
13. Good RA, Zak SJ. Disturbances in gamma globulin synthesis as experiments of nature. Pediatrics. 1956;18:109–49. [PubMed] [Google Scholar]
14. Rosen FS, Janeway CA. The gamma globulins. 3. The antibody deficiency syndromes. N Engl J Med. 1966;275:709–15. doi: 10.1056/NEJM196609292751307. [PubMed] [CrossRef] [Google Scholar]
15. Arvin AM, Pollard RB, Rasmussen LE, Merigan TC. Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest. 1980;65:869–78. doi: 10.1172/JCI109739. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
16. Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K, Arvin AM. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med. 2002;347:26–34. doi: 10.1056/NEJMoa013441. [PubMed] [CrossRef] [Google Scholar]
17. Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation–a randomized double-blind placebo-controlled study. Blood. 2006;107:1800–05. doi: 10.1182/blood-2005-09-3624. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
18. Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis. 2009;200:1068–77. doi: 10.1086/605611. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
19. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–84. doi: 10.1056/NEJMoa051016. [PubMed] [CrossRef] [Google Scholar]
20. Schmader KE, Levin MJ, Gnann JW Jr., McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su S-C, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis. 2012;54:922–28. doi: 10.1093/cid/cir970. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
21. Merck & Co I Zostavax (zoster vaccine live) product insert. 2014:1–12. www.merck.com. online. Accessed 2018 Oct 30.
22. Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, Betts R, Gelb L, Guatelli JC, Harbecke R, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60:900–09. doi: 10.1093/cid/ciu918. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
23. Tseng HF, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY, Bialek S, Hechter RC, Jacobsen SJ. Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years. J Infect Dis. 2016;213:1872–75. doi: 10.1093/infdis/jiw047. [PubMed] [CrossRef] [Google Scholar]
24. Baxter R, Bartlett J, Fireman B, Marks M, Hansen J, Lewis E, Aukes L, Chen Y, Klein NP, Saddier P. Long-term effectiveness of the live zoster vaccine in preventing shingles: a Cohort study. Am J Epidemiol. 2018;187:161–69. doi: 10.1093/aje/kwx245. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
25. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341–49. [PubMed] [Google Scholar]
26. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197:825–35. doi: 10.1086/528696. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
27. Laing KJ, Russell RM, Dong L, Schmid DS, Stern M, Magaret A, Haas JG, Johnston C, Wald A, Koelle DM. Zoster vaccination increases the breadth of CD4+ T cells responsive to varicella zoster virus. J Infect Dis. 2015;212:1022–31. doi: 10.1093/infdis/jiv164. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
28. Sei JJ, Cox KS, Dubey SA, Antonello JM, Krah DL, Casimiro DR, Vora KA. Effector and central memory poly-functional CD4+ and CD8+ T cells are boosted upon ZOSTAVAX® vaccination. Front Immunol. 2015;6:553. doi: 10.3389/fimmu.2015.00553. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
29. Qi Q, Cavanagh MM, Le Saux S, NamKoong H, Kim C, Turgano E, Helman LJ, Kastan MB, Knapp DW, Levin WJ, et al. Diversification of the antigen-specific T cell receptor repertoire after varicella zoster vaccination. Sci Transl Med. 2016;8:332ra46. doi: 10.1126/scitranslmed.aaf0746. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
30. Weinberg A, Canniff J, Rouphael N, Mehta A, Mulligan M, Whattaker J, Levin MJ. VZV-specific cellular immune responses to the live attenuated zoster vaccine in young and older adults. J Immunol. 2017;199:604–12. doi: 10.4049/jimmunol.1700290. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
31. Qi Q, Cavanagh MM, Le Saux S, Wagar LE, Mackey S, Hu J, Maecker H, Swan GE, Davis MM, Dekker CL, et al. Defective T memory cell differentiation after varicella zoster vaccination in older individuals. PLoS Pathog. 2016;12:e1005892. doi: 10.1371/journal.ppat.1005892. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
32. Li S, Sullivan NL, Rouphael N, Yu T, Banton S, Maddur MS, McCausland M, Chiu C, Canniff J, Dubey S, et al. Metabolic phenotypes of response to vaccination in humans. Cell. 2017;169:862–77.e17. doi: 10.1016/j.cell.2017.04.026. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
33. Lelic A, Verschoor CP, Lau VW, Parsons R, Evelegh C, Bowdish DM, Bramson JL, Loeb MB. Immunogenicity of varicella vaccine and immunologic predictors of response in a Cohort of elderly nursing home residents. J Infect Dis. 2016;214:1905–10. doi: 10.1093/infdis/jiw462. [PubMed] [CrossRef] [Google Scholar]
34. Weinberg A, Schmader K, Johnson M, Popmihajlov Z, Tovar-Salazar A, Caldas Y, Pang L, Cho A, Levin M. Immune senescence factors associated with the immunogenicity of a live attenuated zoster vaccine (ZV) in older adults. Open Forum Infect Dis. 2017;4:S413–S4. doi: 10.1093/ofid/ofx163.1036. [CrossRef] [Google Scholar]
35. Beals CR, Railkar RA, Schaeffer AK, Levin Y, Kochba E, Meyer BK, Evans RK, Sheldon EA, Lasseter K, Lang N, et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infect Dis. 2016;16:915–22. doi: 10.1016/S1473-3099(16)00133-X. [PubMed] [CrossRef] [Google Scholar]
36. Levin MJ, Schmader KE, Pang L, Williams-Diaz A, Zerbe G, Canniff J, Johnson MJ, Caldas Y, Cho A, Lang N, et al. Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults. J Infect Dis. 2016;213:14–22. doi: 10.1093/infdis/jiv480. [PubMed] [CrossRef] [Google Scholar]
37. Weinberg A, Popmihajlov Z, Schmader KE, Johnson MJ, Caldas Y, Salazar AT, Canniff J, McCarson BJ, Martin J, Pang L, et al. Persistence of varicella-zoster virus cell-mediated immunity after the administration of a second dose of live herpes zoster vaccine. J Infect Dis. 2018. doi: 10.1093/infdis/jiy514. [PubMed] [CrossRef] [Google Scholar]
38. Cunningham AL.The herpes zoster subunit vaccine. Expert Opin Biol Ther. 2016;16:265–71. doi: 10.1517/14712598.2016.1134481. [PubMed] [CrossRef] [Google Scholar]
39. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–96. doi: 10.1056/NEJMoa1501184. [PubMed] [CrossRef] [Google Scholar]
40. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019–32. doi: 10.1056/NEJMoa1603800. [PubMed] [CrossRef] [Google Scholar]
41. de la Serna J, Campora L, Chandrasekar P, El Idrissi M, Gaidano G, Faqued ML, Oostvolgels L, Schwartz S, Sullivan K, Szer J, et al. LBA2: efficacy and safety of an adjuvanted herpes zoster subunit vaccine in autologous hematopoietic stem cell transplant recipients 18 years of age or older: first results of the phase 3 randomized, placebo-controlled ZOE-HSCT clinical trial. BMT Tandem Meetings; 2018; Salt Lake City, Utah. [Google Scholar]
42. Dendouga N, Fochesato M, Lockman L, Mossman S, Giannini SL. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine. 2012;30:3126–35. doi: 10.1016/j.vaccine.2012.01.088. [PubMed] [CrossRef] [Google Scholar]
43. Leroux-Roels G, Marchant A, Levy J, Van Damme P, Schwarz TF, Horsmans Y, Jilg W, Kremsner PG, Haelterman E, Clément F, et al. Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: results from a phase II, randomized, multicenter trial. Clin Immunol. 2016;169:16–27. doi: 10.1016/j.clim.2016.05.007. [PubMed] [CrossRef] [Google Scholar]
44. Chlibek R, Smetana J, Pauksens K, Rombo L, Van Den Hoek JA, Richardus JH, Plassmann G, Schwarz TF, Ledent E, Heineman TC. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014;32:1745–53. doi: 10.1016/j.vaccine.2014.01.019. [PubMed] [CrossRef] [Google Scholar]
45. Cunningham AL, Levin MJ. Herpes Zoster Vaccines. J Infect Dis. 2018;218:S127–s33. doi: 10.1093/infdis/jiy382. [PubMed] [CrossRef] [Google Scholar]
46. Chlibek R, Pauksens K, Rombo L, van Rijckevorsel G, Richardus JH, Plassmann G, Schwarz TF, Catteau G, Lal H, Heineman TC. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine. 2016;34:863–68. doi: 10.1016/j.vaccine.2015.09.073. [PubMed] [CrossRef] [Google Scholar]
47. Schwarz TF, Volpe S, Catteau G, Chlibek R, David MP, Richardus JH, Lal H, Oostvogels L, Pauksens K, Ravault S, et al. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother. 2018;14:1370–77. doi: 10.1080/21645515.2018.1442162. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
48. Vink P. for the Zoster-028 Study Group Immumnogenicity and safety of a candidate subunit adjuvanted herpes zoster vaccine in adults with solid tumors vaccinated before or after immunosuppressive chemotherapy treatment: A phase II/III, randomized clinical trial. Poster 1349. ID Week. San Diego (CA), 2017. [Google Scholar]
49. Vink P. for the Zoster-041 Study Group Immumnogenicity and safety of a candidate subunit adjuvanted herpes zoster vaccine in adults post renal transplant: A phase III randomized clinical trial. Poster 1348. ID Week 2017. San Diego (CA), 2017. [Google Scholar]
50. Oostvogels L.Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults with hematologic malignancies: A phase III, randomized clinical trial. Abstract 1344. ID Week 2017. San Diego (CA), 2017. [Google Scholar]
51. Levin MJ, Kroehl ME, Johnson MJ, Hammes A, Reinhold D, Lang N, Weinberg A. Th1 memory differentiates recombinant from live herpes zoster vaccines. J Clin Invest. 2018;128:4429–40. doi: 10.1172/JCI121484. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
52. Didierlaurent AM, Collignon C, Bourguignon P, Wouters S, Fierens K, Fochesato M, Dendouga N, Langlet C, Malissen B, Lambrecht BN, et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol. 2014;193:1920–30. doi: 10.4049/jimmunol.1400948. [PubMed] [CrossRef] [Google Scholar]
53. Neeland MR, Shi W, Collignon C, Taubenheim N, Meeusen EN, Didierlaurent AM, de Veer MJ. The lymphatic immune response induced by the adjuvant AS01: a comparison of intramuscular and subcutaneous immunization routes. J Immunol. 2016;197:2704–14. doi: 10.4049/jimmunol.1600817. [PubMed] [CrossRef] [Google Scholar]
54. Coccia M, Collignon C, Herve C, Chalon A, Welsby I, Detienne S, van Helden MJ, Dutta S, Genito CJ, Waters NC, et al. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNgamma response promoting vaccine immunogenicity. NPJ vaccines. 2017;2:25. doi: 10.1038/s41541-017-0027-3. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
55. Redman RL, Nader S, Zerboni L, Liu C, Wong RM, Brown BW, Arvin AM. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis. 1997;176:578–85. [PubMed] [Google Scholar]
56. Eberhardson M, Hall S, Papp KA, Sterling TM, Stek JE, Pang L, Zhao Y, Parrino J, Popmihajlov Z. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with autoimmune disease: A phase 2, randomized, double-blind, placebo-controlled clinical trial. Clin Infect Dis. 2017;65:1174–82. doi: 10.1093/cid/cix484. [PubMed] [CrossRef] [Google Scholar]
57. Mullane KM, Winston DJ, Wertheim MS, Betts RF, Poretz DM, Camacho LH, Pergam SA, Mullane MR, Stek JE, Sterling TM, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J Infect Dis. 2013;208:1375–85. doi: 10.1093/infdis/jit344. [PubMed] [CrossRef] [Google Scholar]
58. Winston DJ, Mullane KM, Boeckh MJ, Cornerly OA, Hurtado K, Su S-C, Pang L, Zhao Y, Chan ISF, Stek JE, et al. A Phase III, double-blind, randomized, placebo-controlled, multicenter clinical trial to study the safety, tolerability, efficacy, and immunogenicity of inactivated Vzv vaccine (ZVIN) in recipients of autologous hematopoietic cell transplants (Auto-HCTs). Abstract #6BMT Tandem MeetingsOrlando (FL), 2017. [Google Scholar]
